Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Financing Activities (2016 - 2025)

Agios Pharmaceuticals' Cash from Financing Activities history spans 14 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 47.19% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $8.7 million, down 39.93%, while the annual FY2025 figure was $8.7 million, 39.93% down from the prior year.
  • Cash from Financing Activities reached $2.6 million in Q4 2025 per AGIO's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $7.3 million in Q1 2021 to a low of -$503.5 million in Q2 2021.
  • Average Cash from Financing Activities over 5 years is -$36.7 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: crashed 32249.3% in 2021, then soared 3750.0% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$18.6 million in 2021, then soared by 100.12% to $22000.0 in 2022, then skyrocketed by 3750.0% to $847000.0 in 2023, then soared by 471.66% to $4.8 million in 2024, then tumbled by 47.19% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Cash from Financing Activities are $2.6 million (Q4 2025), $4.4 million (Q3 2025), and $65000.0 (Q2 2025).